Bioactive compounds in Raphanus sativus: mechanisms of apoptosis, anti-angiogenesis, cell cycle arrest and beyond in cancer prevention and treatment
- PMID: 40652415
- DOI: 10.1007/s12032-025-02894-z
Bioactive compounds in Raphanus sativus: mechanisms of apoptosis, anti-angiogenesis, cell cycle arrest and beyond in cancer prevention and treatment
Abstract
Raphanus sativus or radish is rich in bioactive compounds such as phenolic, antioxidant enzymes, carbohydrates, glucosinolates, terpenes, coumarins, alkaloids, flavonoids (anthocyanin), amino acids, carotenoids, organic acids, and isothiocyanates that have antioxidant and chemopreventive properties. The prominent compounds present in radish are glucosinolates, isothiocyanates, sulforaphane, flavonoids, phenethyl isothiocyanates, etc., that through various mechanisms play an important role in the prevention and treatment of various cancers such as, liver, prostate, colon, oral, lung, cervical, breast, blood, and gastric cancers. The major mechanisms involved are alterations in biotransformation enzymes, such as Phase I and Phase II enzymes, which could help the body detoxify or remove xenobiotics; apoptotic induction caused by secondary glucosinolate metabolites; anti-tumorigenesis through preventing angiogenesis, invasion, migration, and metastasis of cancer cells; using cell cycle arrest to limit the development of cancer cells; anti-proliferation; and antioxidant potential and modulation of epigenetic. These bioactive compounds also exhibit anti-tumor mechanisms that target various cancer cell lines. This review highlights the mechanistic role of various bioactive compounds present in Raphanus sativus for the treatment and prevention of various cancers and also explains their role in various cancer cell lines.
Keywords: Raphanus sativus; Bioactive compounds; Cancer; Flavonoids; Glucosinolates; Isothiocyanates.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no competing interests. There is no conflict of interest of the author regarding the present. Ethical approval: As no animal is being used/sacrificed in the present study, ethical approval was not applicable. Consent to participate: The authors showed consent to participate in this study. Consent to publish: The authors showed consent to publish the study.
References
-
- Rajani C, Borisa P, Karanwad T, Borade Y, Patel V, Rajpoot K, Tekade RK. Cancer-targeted chemotherapy: Emerging role of the folate anchored dendrimer as drug delivery nanocarrier. InPharmaceutical applications of dendrimers 2020 Jan 1 (pp. 151–198). Elsevier.
-
- Packel L. Oncological diseases and disorders. Acute Care Phys Ther. 2024;1:539–88.
-
- Subha ST. Cancer: its alarming trends. Malaysian J Med Health Sci. 2019;15(3):1–3.
-
- Gao Y, Li J, Cheng W, Diao T, Liu H, Bo Y, Liu C, Zhou W, Chen M, Zhang Y, Liu Z. Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation. Cancer Cell. 2024;42(10):1764–83.
-
- Khudhair AY, Hamad RH. Cancer as a Global Health Threat: A Review of Pathogenesis, Prevention, Access to Care and Application of Nanoparticles in Cancer Treatment. Journal of Science in Volume. 2025;3(4).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
